Considerations To Know About LJI308
Kantarjian et al53 assessed the efficacy and security of dasatinib, as as opposed with imatinib, for the main-line remedy of CML-CP. Five hundred and nineteen clients with freshly diagnosed CML-CP had been randomly assigned to get dasatinib in a dose of 100 mg when every day (259 sufferers) or imatinib at a dose of four hundred mg when each day (26